The National Cancer Center announced that the survival rate after 10 years of people diagnosed with cancer at core cancer hospitals nationwide was 53.3% according to the latest tally.
Due to the change in the calculation method from this time, the figures are lower than the previous announcement, but "the figures do not mean that the treatment outcomes have deteriorated, but that the figures reflect the actual situation."

In 2010, the National Cancer Center analyzed the situation of more than 34,10 patients diagnosed with cancer at core cancer hospitals nationwide 10 years after diagnosis.

As a result, the overall survival rate after 53 years, which is an indicator of the effectiveness of cancer treatment, was 3.91%.

By cancer type, the highest is
▽ "papillary cyst carcinoma of the thyroid" at 0.84%, ▽
"prostate cancer" at 3.83%, "breast cancer" in women at 1.79%,


and "endometrial cancer" at 3.5%.

On the other hand
, "pancreatic cancer" is the lowest
at 4.5%, "small cell lung cancer" is 8.12%, "intrahepatic cholangiocarcinoma" is 0.20%,

and "hepatocellular carcinoma" is 4.<>%.


On the Cancer Information Service website, you can also see the survival rate by stage for each site.

The survival rate released this time is lower than the previous figure, but the National Cancer Center says that the reason for this calculation is that the calculation method has been changed from this tally to a new method used internationally.

Dr. Taisuke Ishii of the National Cancer Center says, "It is not that the treatment results have deteriorated, but we believe that the figures reflect the actual situation more by correcting the parts that were previously overestimated."

Types of cancer Data by degree of progression

Data by cancer type and progression are as follows.

Both are shown by a survival rate value called "net survival" that estimates and calculates only those who have died due to cancer.

The overall survival rate is listed in descending order.

▼Papillary cyst cancer
of the thyroid ▽Stage 1: 96.4% ▽Stage 2: 97.1% ▽Stage 3: 96.0% ▽Stage 4: 74.6% ▽Overall: 91.0%





▼ Prostate cancer
▽ Stage 1: 90.6% ▽ Stage 2: 94.4% ▽ Stage 3: 87.2% ▽ Stage 4: 36.9% ▽ Overall: 84.3%





▼Female breast cancer ▽Stage 1: 94.1% ▽Stage 2: 85.8% ▽Stage 3: 63.7% ▽Stage 4: 16.0% ▽Overall: 83.1%





▼Endometrial cancer

▽Stage 1: 92.0% ▽Stage 2: 84.4% ▽Stage 3: 63.8% ▽Stage 4: 16.7% ▽Overall: 79.3%





▼Uterine cancer
▽Stage 1: 91.9% ▽Stage 2: 62.5% ▽Stage 3: 53.1% ▽Stage 4: 18.6% ▽Overall: 68.1%





▼ Kidney cancer
▽Stage 1: 82.4% ▽Stage 2: 70.8% ▽Stage 3: 54.9% ▽Stage 4: 7.3% ▽Overall: 65.7% ▼ Laryngeal cancer ▽ Stage 1: 73.2%







Stage 2: 63.5% ▽ Stage 3: 50.9% ▽ Stage 4: 30.4% ▽ Overall: 58.8% ▽ Colorectal cancer
▽ Stage 1: 80.4%





▽Stage 2: 69.2% ▽Stage 3: 60.9% ▽Stage 4: 11.2% ▽Overall: 57.9% ▽Stomach cancer ▽Stage 1: 77.7% ▽Stage 2: 51.6%







▽Stage 3: 31.5% ▽Stage 4: 6.0% ▽Overall: 57.6% ▼Ovarian cancer
▽Stage 1: 83.8% ▽Stage 2: 58.2%





▽Stage 3: 29.4% ▽Stage 4: 18.5% ▽Overall: 51.9% ▽Bladder cancer ▽Stage 1: 64.8% ▽Stage 2: 43.4%






▽Stage 3: 28.9% ▽Stage 4: 13.3% ▽Overall: 50.1% ▽Renal ureteral cancer ▽Stage 1: 56.6% ▽Stage 2: 52.6%






Stage 3: 42.1% Stage 4: 5.6% Overall: 33.9% Non-small cell lung cancer ▽Stage 1: 62.5% Stage 2: 28.7%






▽Stage 3: 12.7% ▽Stage 4: 2.2% ▽Overall: 30.8% ▽Gallbladder cancer ▽Stage 1: 66.4% ▽Stage 2: 15.4% ▽Stage 3: 3.0%







▽Stage 4: 0.6% ▽Overall: 21.6% ▽Hepatocellular carcinoma
▽Stage 1: 30.5% ▽Stage 2: 18.1% ▽Stage 3: 8.0%





Stage 4: 1.2% Overall: 20.4% Intrahepatic bile duct carcinoma
▽Stage 1: 44.1% ▽Stage 2: 25.3%




Stage 3: 5.0% ▽ Stage 4: 0.5% ▽Overall: 12.0% Small cell lung cancer ▽Stage 1: 22.8% ▽Stage 2: 10.8%






▽Stage 3: 8.3% ▽Stage 4: 0.9% ▽Overall: 5.8% ▼Pancreatic cancer
▽Stage 1: 28.6% ▽Stage 2: 10.3%





▽ Stage 3: 2.8% ▽ Stage 4: 0.8% ▽ Overall: 5.4%



Information on the latest cancer treatments, base hospitals throughout Japan, and counseling and support centers is operated by the National Cancer Center. Cancer Information Service" (ganjoho.jp).